ClinicalTrials.gg
CompletedNCT05686044Updated Apr 29, 2025Results posted

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

A Phase 2/3 interventional study of Buntanetap/Posiphen and Placebo in Alzheimer Disease, sponsored by Annovis Bio Inc.. Completed at 54 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Annovis Bio Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
351
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
276th of 1,609
351 · median 73
Started
2023
with 114 others
Phase 2/3
42 of 1,940
5 open now
Registered
1,553rd of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 276th largest by enrollment of the 1,609 interventional ones that give a count, is one of 115 that started in 2023, is one of 42 in phase 2/3, and was the 1,553rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.

Study details include:

The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home.

The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.

Read the detailed description

320 mild to moderate AD participants will be randomized to 7.5 mg, 15 mg, 30mg of buntanetap/Posiphen once daily (QD) or placebo. If they provide informed consent, they will undergo a Screening Visit, and if they are considered eligible per the inclusion and exclusion criteria, they will proceed to participate in the treatment period. Randomized participants will visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 12 weeks, with daily administration of 7.5 mg, 15 mg or 30 mg of buntanetap/Posiphen or placebo. Participants will be required to visit clinics Day 0 (baseline), 6 weeks, and 12 weeks (end-of-trial), where they will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations) and psychometric tests (Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11), Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-ADL), Digital Symbol Substitution Test (DSST), Mini Mental State Examination (MMSE)). At the end of blood sampling, the participants will need to stay for a minimum of 1 hour of observation. After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur after all clinical visits to assess the participants current condition and if there are any additional adverse events or questions.

The study will be a 12-weeks, placebo-controlled and double-blind trial: participants, investigators and the sponsor will be blinded to the participants' treatment.

Qualified participants will be randomly assigned at a 1:1:1:1 ratio to one of the four treatment arms: buntanetap/Posiphen 7.5 mg, buntanetap/Posiphen 15 mg, buntanetap/Posiphen 30mg, and placebo, through an Interactive Randomization System, after a screening period of up to 42 days.

ADAS-Cog 11, ADCS-CGIC, ADCS-ADL, DSST, and MMSE will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment.

One interim analysis is planned. It will take place when 90 enrolled subjects (\~30%) have completed the Week 6 assessments to re-assess the sample size. No interim analyses are planned for the purpose of stopping the study early for futility.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Alzheimer's disease according to National Institute on Aging and National Institute on Aging and Alzheimer's Association criteria for probable AD
  2. Male or female aged 55 - 85 years.
  3. 14-24.
  4. Have a study partner who will provide written to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant to study visits at designated times.
  5. Female participants of * must have a negative urine pregnancy test at Screening, must be non-lactating and must agree to use a highly effective method of (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for 4 weeks after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used)
    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be in relation to the duration of the study and the preferred and usual lifestyle of the participant) *Non-childbearing potential includes surgically sterilized or with no menstrual bleeding for at least one year prior to study start.
  6. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subject must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
  7. Participants can provide written informed consent. If PI deems that participant cannot fully understand the consent form to give consent, their legally authorized representative (LARs) can provide written informed consent. Participants can comply with scheduled visits, and other study-related procedures to complete the study with the help of the study partner.
  8. No evidence of current suicidal ideation or previous suicide attempt in the past 2 months as evaluated in the Columbia Suicide Severity Rating Scale nor suicidal behavior in the past 6 months as per investigator.
  9. Stability of permitted medications for at least 4 weeks prior to screening.

    1. Cholinesterase inhibitors and/or memantine medication
    2. Anticonvulsant medications used for epilepsy or mood stabilization, neuropathic pain indications.
    3. Mood-stabilizing psychotropic agents, including, but not limited to, lithium.
  10. Adequate visual and hearing ability (physical ability to perform all the study assessments) as per investigator.
  11. Good general health with no disease expected to interfere with the study as per investigator.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the (DSM). Mild depression or history of depression that is stable on treatment with a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) medication at a stable dose is acceptable.
  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, Parkinson disease dementia, B12 and thyroid deficiency caused dementia.
  3. History of a seizure disorder, if stable on medication is acceptable.
  4. Has a history or current evidence of long syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and 460 ms for women, or torsades de pointes.
  5. Has bradycardia (\<50 bpm) or tachycardia (>100 bpm) on the at screening.
  6. Has uncontrolled Type-1 or Type-2 diabetes. A subject with levels up to 7.5% can be enrolled if the investigator believes the subject's diabetes is under control.
  7. Has renal ( with normal \<60 mL/min/BSA (body surface area) or hepatic impairment (ALP > 2.0 and/or total > 2.0 ULN) .
  8. Has any clinically significant abnormal laboratory values. Participants with liver function tests ( [AST] or alanine aminotransferase [ALT]) greater than twice the upper limit of normal will be excluded.
  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C SSRS, or of harm to others in the opinion of the Investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e. g. positive response to Items 4 or 5 in assessment of suicidal ideation on the C SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
  10. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence. (Participants with stable untreated prostate cancer or skin cancers are not excluded).
  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
  12. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater.

    The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. Participants with learning disability or developmental delay.
  14. Participants whom the site PI deems to be otherwise ineligible.
  15. Participants with a known allergy to the investigational drug or any of its components. Here are all the inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Magnesium Stearate
    • Hypromellose (capsule shells structure)
    • titanium dioxide (opacifier of the capsule shells)
  16. Subject is currently pregnant, breast-feeding and/or lactating.
  17. Subject is currently taking strong and moderate inhibitors and/or inducers. (e.g., CYP3A4 inhibitors Itraconazole, Ketoconazole, Azamulin, Troleandomycin, Verapamil; CYP3A4 inducers Rifampicin)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
351 participants (actual)

Study arms

  • Experimental
    7.5mg Buntanetap/Posiphen

    Buntanetap/Posiphen 7.5mg oral capsule with daily administration for a period of 12 weeks

    Drug: Buntanetap/Posiphen

  • Experimental
    15mg Buntanetap/Posiphen

    Buntanetap/Posiphen 15mg oral capsule with daily administration for a period of 12 weeks

    Drug: Buntanetap/Posiphen

  • Experimental
    30mg Buntanetap/Posiphen

    Buntanetap/Posiphen 30mg oral capsule with daily administration for a period of 12 weeks

    Drug: Buntanetap/Posiphen

  • Placebo comparator
    Placebo

    Placebo oral capsule with daily administration for a period of 12 weeks

    Drug: Placebo

Interventions

  • DrugBuntanetap/Posiphen

    Drug page: Buntanetap

    HPMC (vegetarian source) capsule shells

    Also known as: Posiphen Tartrate

  • DrugPlacebo

    HPMC (vegetarian source) capsule shells

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in ADAS-Cog11

    Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) measures cognitive functions and non-cognitive functions such as mood and behavior. It was designed to measure the cognitive and behavioral domains known to be affected in Alzheimer disease, including memory, language, orientation, construction, and planning of simple designs, and completed simple goal-oriented behaviors. Specifically, the ADAS-Cog comprises ratings from 11 components: word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering test instructions, spoken language, word finding, and comprehension. Total scores range from 0-70, with higher scores indicating greater cognitive impairment.

    Time frame: Baseline to the end of treatment period (12 weeks)

  2. ADCS-CGIC at Week 12

    Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of informants. The ADCS-CGIC measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). Lower scores indicate better improvement.

    Time frame: Baseline to the end of treatment period (12 weeks)

Secondary outcomes

  1. Change From Baseline to Week 12 in ADCS-ADL

    Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory scale developed as a rater-administered questionnaire answered by the participant's study partner. The ADCS-ADL measures 6 basic activities of daily living (BADL) items and 17 instrumental activities of daily living (IADL) items that provide a total score from 0-78, with a lower score indicating greater severity. Basic activities include basic self-care tasks such as feeding, mobility, toileting, bathing, grooming and dressing. Instrumental activities are more complex and vary based on cultural norms, gender roles. As such, instrumental activities tend to include a broad range of activities. Caregivers are asked to rate the degree to which their family member or loved one can perform a variety of tasks. The assessed activities provide a total score from 0-78. Participants with a lower score indicates greater severity.

    Time frame: Baseline to end of treatment period (12 weeks)

Other outcomes

  1. Change From Baseline to Week 12 in Plasma Biomarkers

    Plasma biomarkers measured: Glial fibrillary acidic protein (GFAP), Neurofilament light (NFL), TAR DNA-binding protein 43 (TDP43)

    Time frame: Baseline to the end of treatment period (12 weeks)

07

Results

Posted Apr 29, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
Started89888787
Completed82848079
Not completed7478

Outcome measures

PrimaryChange From Baseline to Week 12 in ADAS-Cog11

Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) measures cognitive functions and non-cognitive functions such as mood and behavior. It was designed to measure the cognitive and behavioral domains known to be affected in Alzheimer disease, including memory, language, orientation, construction, and planning of simple designs, and completed simple goal-oriented behaviors. Specifically, the ADAS-Cog comprises ratings from 11 components: word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering test instructions, spoken language, word finding, and comprehension. Total scores range from 0-70, with higher scores indicating greater cognitive impairment.

Time frame:
Baseline to the end of treatment period (12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in ADAS-Cog11
units on a scalePlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
Change From Baseline to Week 12 in ADAS-Cog11-2.32 ± 0.533-1.34 ± 0.526-3.01 ± 0.534-2.24 ± 0.531
PrimaryADCS-CGIC at Week 12

Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of informants. The ADCS-CGIC measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). Lower scores indicate better improvement.

Time frame:
Baseline to the end of treatment period (12 weeks)
Reported as:
Least squares mean · score on a scale
ADCS-CGIC at Week 12
score on a scalePlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
ADCS-CGIC at Week 123.58 ± 0.1293.96 ± 0.1283.61 ± 0.1313.83 ± 0.132
SecondaryChange From Baseline to Week 12 in ADCS-ADL

Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory scale developed as a rater-administered questionnaire answered by the participant's study partner. The ADCS-ADL measures 6 basic activities of daily living (BADL) items and 17 instrumental activities of daily living (IADL) items that provide a total score from 0-78, with a lower score indicating greater severity. Basic activities include basic self-care tasks such as feeding, mobility, toileting, bathing, grooming and dressing. Instrumental activities are more complex and vary based on cultural norms, gender roles. As such, instrumental activities tend to include a broad range of activities. Caregivers are asked to rate the degree to which their family member or loved one can perform a variety of tasks. The assessed activities provide a total score from 0-78. Participants with a lower score indicates greater severity.

Time frame:
Baseline to end of treatment period (12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in ADCS-ADL
units on a scalePlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
Change From Baseline to Week 12 in ADCS-ADL2.03 ± 0.811-0.14 ± 0.8061.71 ± 0.8310.15 ± 0.822
Other pre-specifiedChange From Baseline to Week 12 in Plasma Biomarkers

Plasma biomarkers measured: Glial fibrillary acidic protein (GFAP), Neurofilament light (NFL), TAR DNA-binding protein 43 (TDP43)

Time frame:
Baseline to the end of treatment period (12 weeks)
Reported as:
Mean · pg/ml
Change From Baseline to Week 12 in Plasma Biomarkers
pg/mlPlacebo30mg Buntanetap/Posiphen
GFAP5.5 ± 74.322.1 ± 69.44
NFL0.4 ± 6.88-2.5 ± 14.05
TDP43-467.5 ± 1474-985.1 ± 4950
Post-hocChange From Baseline to Week 12 in ADAS-Cog11 for Biomarker Positive Participants With Baseline MMSE Scores 21-24

Change in the ADAS-Cog11 score from Baseline to the End of Trial. Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) measures cognitive functions and non-cognitive functions such as mood and behavior. It was designed to measure the cognitive and behavioral domains known to be affected in Alzheimer disease, including memory, language, orientation, construction, and planning of simple designs, and completed simple goal-oriented behaviors. Specifically, the ADAS-Cog comprises ratings from 11 components: word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering test instructions, spoken language, word finding, and comprehension. Total scores range from 0-70, with higher scores indicating greater cognitive impairment.

Time frame:
Baseline to the end of treatment period (12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in ADAS-Cog11 for Biomarker Positive Participants With Baseline MMSE Scores 21-24
units on a scalePlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
Change From Baseline to Week 12 in ADAS-Cog11 for Biomarker Positive Participants With Baseline MMSE Scores 21-24-0.26 ± 0.911-2.19 ± 0.865-2.79 ± 0.815-3.32 ± 0.820

Adverse events

Collected over From consent to end of trial (up to 5 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/88 (0%)3/88 (3.4%)1/88 (1.1%)
7.5mg Buntanetap/Posiphen0/86 (0%)0/86 (0%)5/86 (5.8%)
15mg Buntanetap/Posiphen0/85 (0%)0/85 (0%)1/85 (1.2%)
30mg Buntanetap/Posiphen0/87 (0%)3/87 (3.4%)1/87 (1.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
PneumoniaInfections and infestations1/880/860/851/87
OsteoarthritisMusculoskeletal and connective tissue disorders0/880/860/851/87
Soft tissue massMusculoskeletal and connective tissue disorders0/880/860/851/87
DehydrationMetabolism and nutrition disorders0/880/860/851/87
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/880/860/851/87
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/880/860/851/87
Urinary tract infectionInfections and infestations1/880/860/850/87
Cardiac failure congestiveCardiac disorders1/880/860/850/87
OesophagitisGastrointestinal disorders1/880/860/850/87
Most frequent other events
Most frequent other events
EventPlacebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/Posiphen
DizzinessNervous system disorders1/885/861/851/87

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/PosiphenTotal
Mean73.1 ± 6.9773.6 ± 7.2874.7 ± 6.0673.1 ± 6.1573.6 ± 6.64
Sex: Female, Male
Sex: Female, Male(Participants)Placebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/PosiphenTotal
Female52574457210
Male37314330141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/PosiphenTotal
Hispanic or Latino36333243144
Not Hispanic or Latino53555544207
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/PosiphenTotal
American Indian or Alaska Native00000
Asian12317
Native Hawaiian or Other Pacific Islander00112
Black or African American765725
White80787777312
More than one race01012
Unknown or Not Reported11103
Mini-Mental State Examination (MMSE)
Mini-Mental State Examination (MMSE)(units on a scale)Placebo7.5mg Buntanetap/Posiphen15mg Buntanetap/Posiphen30mg Buntanetap/PosiphenTotal
Mean20.2 ± 3.0419.6 ± 3.2320.0 ± 3.0620.0 ± 2.8220.0 ± 3.04
08

Study locations

54 sites
  • CCT Research - Gilbert Neurology Partners
    Gilbert, Arizona 85297, United States
  • CCT Research - Foothills Center
    Phoenix, Arizona 85004, United States
  • The Belinga Clinic
    Fort Smith, Arkansas 72916, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • CenExel Clinical Clinical Research, Inc
    Los Alamitos, California 90720, United States
  • Cenexel Rocky Mountain Clinical Research
    Englewood, Colorado 80113, United States
  • Ki Health Partners LLC D/B/A New England Institute for Clinical Research
    Stamford, Connecticut 06824, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • K2 Medical Research
    Clermont, Florida 34711, United States
  • The Neurology Institute - Coral Springs
    Coral Springs, Florida 33067-4640, United States
  • JY Research Inst.
    Cutler Bay, Florida 33189, United States
  • Arrow Clinical trial
    Daytona Beach, Florida 32114, United States
  • Accel Research Sites - DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • New Life Medical Research Center
    Hialeah, Florida 33012, United States
  • CenExel RCA
    Hollywood, Florida 33024, United States
  • Coral Clinic Reserach LLC
    Homestead, Florida 33032, United States
  • Charter Research
    Lady Lake, Florida 32159, United States
  • ClinCloud, LLC
    Maitland, Florida 32751, United States
  • K2 Medical Research
    Maitland, Florida 32751, United States
  • Merritt Island Clinical Research LLC
    Merritt Island, Florida 32952, United States
  • Premier Clinical Research Institute, Inc
    Miami, Florida 33122, United States
  • Gold Coast Health Research, LLC
    Miami, Florida 33155, United States
  • Medical Professional Clinical Research Center, Inc
    Miami, Florida 33165, United States
  • Reliant Medical Research
    Miami, Florida 33165, United States
  • Ezy Medical Research Co.
    Miami, Florida 33175, United States
  • Nuovida Research Center
    Miami, Florida 33186, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Visionary Investigators Network
    Pembroke Pines, Florida 33026, United States
  • Napa Research
    Pompano Beach, Florida 33064, United States
  • K2 Medical Research
    Tampa, Florida 33067, United States
  • K2 Summit Research
    The Villages, Florida 32159, United States
  • ClinCloud, LLC
    Viera, Florida 32940, United States
  • Conquest Research, LLC
    Winter Park, Florida 32789, United States
  • Charter Research
    Winter Park, Florida 32792, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • Center for Advanced Research & Education
    Gainesville, Georgia 30501, United States
  • Hawaii Pacific Neuroscience, LLC
    Honolulu, Hawaii 96817, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Josephson Wallack Munshower Neurology, P.C.
    Indianapolis, Indiana 46256, United States
  • Northern Light Acadia Hospital
    Bangor, Maine 04401, United States
  • MedVadis Research
    Waltham, Massachusetts 02451, United States
  • Quest Research Institue
    Farmington Hills, Michigan 48334, United States
  • Insight Research Institute
    Flint, Michigan 48507, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • CenExel Clinical Research, Inc
    Toms River, New Jersey 08755, United States
  • Velocity Clinical Research
    Syracuse, New York 13057, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Neuroscience Centre (CINAC)
    Canton, Ohio 44718, United States
  • Dayton Center for Neurological Disorders, Inc
    Centerville, Ohio 45459, United States
  • NeuroCare Plus
    Houston, Texas 77094, United States
  • Be Well Clinical Studies, LLC
    Round Rock, Texas 78681, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Inland Northwest Research
    Spokane, Washington 99202-1342, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Feb 2024, 10 months.

Results were first posted in Apr 2025, 1 year 2 months after primary completion.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 17, 2023
StartActual
Apr 1, 2023
Primary completionActual
Feb 13, 2024
CompletionActual
Feb 13, 2024
Results first posted
Apr 29, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05686044
Lead sponsor
Annovis Bio Inc.
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Apr 1, 2023
Primary completion
Feb 13, 2024
Completion
Feb 13, 2024
Results posted
Apr 29, 2025
Last update
Apr 29, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buntanetap

Start the discussion